Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Screener

DARE

Dare Bioscience Inc

May 16 • 04:00PM ET

0.4348

Dollar change +0.0748
Percentage change 20.78	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.31	Insider Own	1.71%	Shs Outstand	99.97M	Perf Week	38.65%
Market Cap	43.95M	Forward P/E	-	EPS next Y	-0.14	Insider Trans	0.00%	Shs Float	99.36M	Perf Month	53.80%
Income	-28.87M	PEG	-	EPS next Q	0.00	Inst Own	6.76%	Short Float	0.29%	Perf Quarter	18.90%
Sales	2.82M	P/S	15.59	EPS this Y	50.00%	Inst Trans	1.48%	Short Ratio	0.41	Perf Half Y	26.99%
Book/sh	-0.11	P/B	-	EPS next Y	21.90%	ROA	-133.12%	Short Interest	0.29M	Perf Year	-58.59%
Cash/sh	0.04	P/C	12.11	EPS next 5Y	-	ROE	-994.69%	52W Range	0.27 - 1.06	Perf YTD	40.71%
Dividend Est.	-	P/FCF	-	EPS past 5Y	26.02%	ROI	-	52W High	-58.98%	Beta	1.32
Dividend TTM	-	Quick Ratio	0.56	Sales past 5Y	-14.38%	Gross Margin	98.59%	52W Low	61.04%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	0.56	EPS Y/Y TTM	13.75%	Oper. Margin	-1010.65%	RSI (14)	65.36	Volatility	11.55% 10.70%
Employees	26	Debt/Eq	-	Sales Y/Y TTM	-71.83%	Profit Margin	-1024.93%	Recom	1.00	Target Price	4.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	28.51%	Payout	-	Rel Volume	1.30	Prev Close	0.36
Sales Surprise	-96.43%	EPS Surprise	-16.67%	Sales Q/Q	-	Earnings	May 14 BMO	Avg Volume	704.43K	Price	0.43
SMA20	41.89%	SMA50	5.59%	SMA200	-1.09%	Trades		Volume	913,941	Change	20.78%

May-15-24 12:27PM	Q1 2024 Dare Bioscience Inc Earnings Call (Thomson Reuters StreetEvents) +14.29%
03:13AM	Dare Bioscience Inc (DARE) (Q1 2024) Earnings Call Transcript Highlights: Strategic Moves Amid ... (GuruFocus.com)
May-14-24 12:53PM	DARE Stock Earnings: Dare Bioscience Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:00AM	Dar Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire)
May-07-24 08:00AM	Dar Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024 (GlobeNewswire)
08:00AM	Loading…
May-02-24 08:00AM	Dar Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network (GlobeNewswire) -5.43%
08:00AM	Dare Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network (GlobeNewswire)
Apr-30-24 07:30AM	Dar Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts (GlobeNewswire) +9.08%
07:30AM	Dare Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts (GlobeNewswire)
Apr-23-24 08:00AM	Dar Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 (GlobeNewswire)
08:00AM	Dare Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 (GlobeNewswire)
Apr-11-24 08:00AM	Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive (GlobeNewswire)
Apr-01-24 04:05PM	Dar Bioscience, Inc. (NASDAQ:DARE) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 09:07AM	Q4 2023 Dare Bioscience Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-28-24 01:53PM	DARE Stock Earnings: Dare Bioscience Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -10.71%
08:00AM	Loading…
08:00AM	Dar Bioscience Reports Full Year 2023 Financial Results and Provides Company Update (GlobeNewswire)
Mar-21-24 08:00AM	Dare Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024 (GlobeNewswire)
08:00AM	Dar Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024 (GlobeNewswire)
Feb-22-24 08:00AM	Dare Bioscience to Present at the International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting (GlobeNewswire) +21.61%
Jan-31-24 08:00AM	Dare Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024 (GlobeNewswire)
Jan-26-24 04:30PM	Dare Bioscience Announces Executive Team and Board of Directors Changes (GlobeNewswire) +5.14%
Jan-17-24 08:00AM	Dar Bioscience Announces Grant to Support Biotherapeutic Product Development (GlobeNewswire)
Jan-04-24 08:00AM	Dare Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases (GlobeNewswire) +10.24%
Dec-26-23 08:00AM	Dar Bioscience Secures $12 million in Royalty-backed Investment Structure (GlobeNewswire)
Dec-20-23 08:00AM	Dare Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study (GlobeNewswire)
Dec-13-23 08:00AM	Dar Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study (GlobeNewswire)
Dec-07-23 08:00AM	Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause (GlobeNewswire) -7.89%
Dec-04-23 08:00AM	Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive (GlobeNewswire)
Nov-23-23 03:38PM	20 Countries with the Highest Teenage Pregnancy Rates (Insider Monkey)
Nov-20-23 08:00AM	Dar Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Dar 's Novel Women's Health Programs (GlobeNewswire)
08:00AM	Loading…
Nov-13-23 08:00AM	Dar Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting (GlobeNewswire) +5.79%
Nov-10-23 10:16AM	Dar Bioscience, Inc. (NASDAQ:DARE) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 08:00AM	Dar Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update (GlobeNewswire) -6.93%
Nov-06-23 08:00AM	Dar Bioscience to Participate in Three November Conferences (GlobeNewswire) -8.63%
Nov-02-23 08:00AM	Dar Bioscience to Host Third Quarter 2023 Financial Results and Company Update Conference Call and Webcast on November 9, 2023 (GlobeNewswire)
Nov-01-23 08:00AM	Dar Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program (GlobeNewswire)
Oct-16-23 08:00AM	Dar Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO (Clindamycin Phosphate) Vaginal Gel, 2%, FDA-Approved Treatment for Bacterial Vaginosis in Females 12 Years or Older (GlobeNewswire) +14.30%
Sep-21-23 08:00AM	Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 (GlobeNewswire)
Sep-20-23 08:00AM	Daré Bioscience to Present at The Menopause Society 2023 Annual Meeting (GlobeNewswire)
Sep-06-23 08:00AM	Daré Bioscience to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.30%
Sep-05-23 08:00AM	Daré Bioscience Completes Previously Announced Equity Financing (GlobeNewswire)
Aug-30-23 08:00AM	Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (GlobeNewswire)
Aug-12-23 09:35AM	Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 09:30AM	Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update (GlobeNewswire)
Aug-09-23 08:00AM	Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of DARE-HRT1 Intravaginal Rings (GlobeNewswire)
Aug-03-23 08:00AM	Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023 (GlobeNewswire)
Jul-31-23 08:00AM	Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth (GlobeNewswire)
Jul-29-23 08:53AM	Investors in Daré Bioscience (NASDAQ:DARE) have unfortunately lost 33% over the last five years (Simply Wall St.)
Jul-11-23 05:30PM	Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems (GlobeNewswire)
08:00AM	Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women (GlobeNewswire)
Jul-06-23 08:00AM	Daré Bioscience Announces Upcoming Webinar to Review Additional Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder (GlobeNewswire)
Jul-05-23 08:00AM	Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (GlobeNewswire) -6.59%
Jun-21-23 08:00AM	Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Postmenopausal Women (GlobeNewswire)
Jun-18-23 09:55AM	We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jun-14-23 08:00AM	Daré Bioscience to Present at the Maxim Group Virtual Healthcare Conference (GlobeNewswire)
Jun-09-23 08:00AM	Daré Bioscience Announces Publication of Phase 1/2 Pharmacokinetic, Safety and Pharmacodynamic Data for DARE-VVA1 - a Potential New Hormone-Free Treatment for Vulvovaginal Atrophy - in Climacteric, the Journal of the International Menopause Society (GlobeNewswire)
Jun-05-23 08:00AM	Daré Bioscience Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder (GlobeNewswire)
Jun-01-23 08:00AM	Daré Bioscience to Participate in Two Upcoming Conferences: 2023 BIO International Convention and the Longwood Healthcare Leaders Spring 2023 MIT Conference (GlobeNewswire)
May-31-23 08:00AM	Daré Bioscience Announces Availability of Publication on the Patient-Centered Concept Elicitation Study for Female Sexual Arousal Disorder in The Journal of Sexual Medicine (GlobeNewswire)
May-16-23 12:06PM	Daré Bioscience, Inc. (NASDAQ:DARE) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-11-23 09:25AM	Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update (GlobeNewswire)
May-04-23 08:00AM	Daré Bioscience to Host First Quarter 2023 Financial Results and Company Update Conference Call and Webcast on May 11, 2023 (GlobeNewswire)
Apr-20-23 08:00AM	Daré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6% (GlobeNewswire)
Apr-19-23 08:00AM	David Friend, Ph.D., Chief Scientific Officer of Daré Bioscience, Inc., to Present at the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, Germany (GlobeNewswire)
Apr-18-23 08:00AM	Daré Bioscience Announces Publication of Positive Safety and Acceptability Data from Phase 1 Clinical Trial that Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone Therapy (GlobeNewswire)
Apr-17-23 08:00AM	Daré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Womens Health Business Conference (GlobeNewswire)
Mar-30-23 08:00AM	Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update (GlobeNewswire)
Mar-23-23 08:00AM	Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023 (GlobeNewswire)
Mar-01-23 08:00AM	Daré Bioscience to Present at the 35th Annual Roth Conference (GlobeNewswire)
Feb-22-23 08:00AM	Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1 (GlobeNewswire)
Feb-01-23 08:00AM	Daré Bioscience to Participate in Three February Conferences (GlobeNewswire)
Jan-26-23 08:00AM	Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause (GlobeNewswire)
Jan-21-23 07:16AM	Daré Bioscience (NASDAQ:DARE) investors are sitting on a loss of 49% if they invested five years ago (Simply Wall St.)
Jan-09-23 12:00PM	All You Need to Know About Dare Bioscience, Inc. (DARE) Rating Upgrade to Strong Buy (Zacks) +12.82%
08:00AM	Daré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause (GlobeNewswire)
Dec-12-22 08:00AM	Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea (GlobeNewswire)
Dec-11-22 09:58AM	We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully (Simply Wall St.)
Nov-15-22 12:00PM	Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
08:00AM	Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health (GlobeNewswire)
Nov-14-22 08:00AM	Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study (GlobeNewswire)
Nov-10-22 07:05AM	Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
05:45AM	Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update (GlobeNewswire)
Nov-08-22 08:00AM	Daré Bioscience to Present at the Stifel 2022 Healthcare Conference (GlobeNewswire)
Nov-03-22 08:00AM	Daré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Conference Call and Webcast on November 10, 2022 (GlobeNewswire)
Nov-01-22 08:00AM	Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete (GlobeNewswire)
Oct-17-22 08:00AM	Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study (GlobeNewswire)
Oct-10-22 08:00AM	Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive (GlobeNewswire)
Sep-15-22 08:00AM	Daré Bioscience to Participate in Two Upcoming Conferences (GlobeNewswire)
Sep-06-22 08:00AM	Daré Bioscience to Participate in H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-29-22 08:00AM	Daré Bioscience Announces Interim Analysis of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder (GlobeNewswire)
Aug-24-22 08:00AM	Daré Bioscience, Inc. Announces Global Licensing Rights to the Novel Antimicrobial Glycerol Monolaurate for Vaginal Health (GlobeNewswire)
Aug-12-22 06:53AM	Daré Bioscience (NASDAQ:DARE) shareholders have endured a 58% loss from investing in the stock five years ago (Simply Wall St.)
Aug-09-22 08:00AM	Daré Bioscience Reports Second Quarter 2022 Financial Results and Provides a Company Update (GlobeNewswire)
Aug-02-22 08:00AM	Daré Bioscience to Host Second Quarter 2022 Financial Results and Company Update Conference Call and Webcast on August 9, 2022 (GlobeNewswire) +7.41%
Jul-07-22 08:00AM	Daré Bioscience to Participate in Maxim Group Womens Health Panel (GlobeNewswire)
Jul-04-22 10:14AM	We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jun-30-22 08:00AM	Daré Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (GlobeNewswire)
Jun-27-22 02:40PM	EVFM Stock: Contraception Maker Evofem Biosciences Doubles After Roe Decision (InvestorPlace) +6.98%

Dare Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.

DARE

Dare Bioscience Inc

Upgrade your FINVIZ experience